Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Michael Rosenzweig, Yvonne Efebera, Efstathios Kastritis, Brandon Blue, Faizi Jamal, Monique C Minnema, Christopher Pericone, Sandra Vasey, Yuping Chen, Sonja Kotoulek, Bart Vandael, Joana Duran, Samer Khaled, NamPhuong Tran, Jessica Vermeulen, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2023-181953

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C Minnema, Meletios A. Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj Merzoug, Elena Papachristou, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2023) 142 (Supplement 1): 539.

https://doi.org/10.1182/blood-2023-185811

Published: 2023

Journal Articles

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Blood (2023) 142 (Supplement 1): 1063.

https://doi.org/10.1182/blood-2023-178798

Published: 2023

Journal Articles

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Ajai Chari, Albert Oriol, Amrita Krishnan, Maria Del Carmen Martinez Chamorro, Luciano Costa, Maria Victoria Mateos, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, M. Damiette Smit, Swarna Ramanjulu, Paula Rodríguez Otero

Blood (2023) 142 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2023-181228

Published: 2023

Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2023-182330

Published: 2023

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C Minnema, Ashutosh D. Wechalekar, Elena Papachristou, Giorgos Psarros, Pieter Sonneveld, Stefan Schonland

Blood (2023) 142 (Supplement 1): 4779.

https://doi.org/10.1182/blood-2023-185861

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C. Minnema, Meletios-Athanasios Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2022) 140 (Supplement 1): 1841–1843.

https://doi.org/10.1182/blood-2022-168757

Published: 2022

Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Blood (2022) 140 (Supplement 1): 2283–2285.

https://doi.org/10.1182/blood-2022-156085

Published: 2022

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C. Minnema, Ashutosh D. Wechalekar, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Stefan Schönland

Blood (2022) 140 (Supplement 1): 7294–7296.

https://doi.org/10.1182/blood-2022-169688

Published: 2022

Journal Articles

Prediction of Poor Outcome after Tisagenlecleucel in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Using Artificial Intelligence Analysis of Pre-Infusion PET/CT

Margot Jak, Bas H.M. van der Velden, Bart de Keizer, Sjoerd G Elias, Monique C. Minnema, Kenneth G.A. Gilhuijs

Blood (2022) 140 (Supplement 1): 1919–1920.

https://doi.org/10.1182/blood-2022-158543

Published: 2022

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 4447–4449.

https://doi.org/10.1182/blood-2022-162555

Published: 2022

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Blood (2022) 140 (Supplement 1): 4420–4422.

https://doi.org/10.1182/blood-2022-165942

Published: 2022

Journal Articles

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Blood (2022) 140 (Supplement 1): 4409–4411.

https://doi.org/10.1182/blood-2022-156390

Published: 2022

Journal Articles

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Blood (2022) 140 (Supplement 1): 3158–3161.

https://doi.org/10.1182/blood-2022-158248

Published: 2022

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Blood (2022) 140 (Supplement 1): 10399–10401.

https://doi.org/10.1182/blood-2022-156117

Published: 2022

Journal Articles

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 384–387.

https://doi.org/10.1182/blood-2022-159707

Published: 2022

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Blood (2021) 138 (Supplement 1): 153.

https://doi.org/10.1182/blood-2021-152675

Published: 2021

Journal Articles

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Amrita Y. Krishnan, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodriguez-Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Raluca I. Verona, Xuewen Ma, Suzette Girgis, Shiyi Yang, Brandi W. Hilder, Jeffery Russell, Jenna D. Goldberg, Ajai Chari

Blood (2021) 138 (Supplement 1): 158.

https://doi.org/10.1182/blood-2021-146868

Published: 2021

Journal Articles

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Natalie S. Callander, Vincent Ribrag, Paul G. Richardson, Ajay K. Nooka, Kevin Song, Katarina Uttervall, Monique C. Minnema, Katja Weisel, Hang Quach, Chang-Ki Min, Marc S. Ballas, Xiaofang Li, Nirav Ratia, Morrys Kaisermann, Beata Holkova, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 897.

https://doi.org/10.1182/blood-2021-152662

Published: 2021

NARROW

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Prediction of Poor Outcome after Tisagenlecleucel in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Using Artificial Intelligence Analysis of Pre-Infusion PET/CT

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only